140 related articles for article (PubMed ID: 25842735)
1. Postmarketing evaluation on the safety and effectiveness of deng-zhanxixin injection made from Dengzhanxixin (Herba Erigerontis Breviscapi).
Li Y; Lin G; Xie Y; Zhang W; Guo T
J Tradit Chin Med; 2015 Feb; 35(1):99-103. PubMed ID: 25842735
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing studies on safety of Dengfeng shenmai injection.
Wang L; Zhang W; Xie Y; Bai Y; Wang M; Ai Q
J Tradit Chin Med; 2013 Dec; 33(6):827-31. PubMed ID: 24660618
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
4. [Changes of mitochondrial apoptosis in spinal cord ischemia-reperfusion injury and the effects of Herba Erigerontis Breviscapi Injection preconditioning intervention in rabbits].
Cheng B; Wang X; Wang L; Cao K; Duan L; Li FT
Zhong Xi Yi Jie He Xue Bao; 2009 Sep; 7(9):842-7. PubMed ID: 19747440
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing safety evaluation: depside salt injection made from Danshen (Radix Salviae Miltiorrhizae).
Chang Y; Zhang W; Xie Y; Xu X; Sun R; Wang Z; Yan R
J Tradit Chin Med; 2014 Dec; 34(6):749-53. PubMed ID: 25618981
[TBL] [Abstract][Full Text] [Related]
6. [Clinical safety imtensive hospital monitoring on Shenfu injection with 30 106 cases].
Wang ZF; Yu JY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2871-2876. PubMed ID: 29139250
[TBL] [Abstract][Full Text] [Related]
7. [Meta-analysis of Dengzhanxixin injection treatment for unstable angina pectoris].
Nie XL; Shen H; Xie YM; Hu J; Zhang YL; Li YY
Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2768-73. PubMed ID: 23285930
[TBL] [Abstract][Full Text] [Related]
8. Establishment of safety evidence for Xingxue Shuxuening injection.
Yang W; Zhang W; Xie Y; Han B
J Tradit Chin Med; 2014 Oct; 34(5):604-8. PubMed ID: 25417413
[TBL] [Abstract][Full Text] [Related]
9. [Post-marketing surveillance of
Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
[No Abstract] [Full Text] [Related]
10. [Post-marketing study on clinical safety of ginkgo diterpene lactone meglumine injection in 6 300 patients with ischemic stroke].
Zhou L; Gao Y; Lai XX; Xu TS; Yu M; Wang Y; Zhao JJ; Tan ZH
Zhongguo Zhong Yao Za Zhi; 2017 Dec; 42(24):4744-4749. PubMed ID: 29493141
[TBL] [Abstract][Full Text] [Related]
11. [Post-marketed re-evaluation of fleabane injection and Dengzhan Shengmai capsule study on treatment in patients with ischemic stroke].
Wei X; Ye X; Xie Y; Zou Y; Zhao X; Han J; Wang X; Ma Y; Bi Q; Xie Q; Zhao J; Cao X; Chen H; Wang S; Yan R; Han Z; Yi D; Wang Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2789-92. PubMed ID: 22292366
[TBL] [Abstract][Full Text] [Related]
12. [Preliminary study on general safe medication regularity of Chinese patent orthopedic medicines based on adverse reaction/event literature analysis].
Wang YG; Shi XY; Jin R; Li HY; Kong XW; Qiao YJ
Zhongguo Zhong Yao Za Zhi; 2015 Mar; 40(6):1192-7. PubMed ID: 26226769
[TBL] [Abstract][Full Text] [Related]
13. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
[TBL] [Abstract][Full Text] [Related]
14. [Literature review on premarketing and postmarketing evidence of xiyanping injection].
Wang ZF; Chen X; Zhang W; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3637-40. PubMed ID: 25532411
[TBL] [Abstract][Full Text] [Related]
15. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
16. [Post-marketing clinical safety assessment of Shenmai injection based on active monitoring and passive monitoring in large data background].
Wang LX; Xie YM; Ai QH; Song NB
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4752-6. PubMed ID: 27245017
[TBL] [Abstract][Full Text] [Related]
17. [Data-mining characteristics of adverse drug reactions and pharmacovi-gilance of Chinese patent drugs including Aconitum herbs].
Zhang XM; Li F; Zhang B; Chen XF; Piao JZ
Zhongguo Zhong Yao Za Zhi; 2018 Jan; 43(2):216-221. PubMed ID: 29552835
[TBL] [Abstract][Full Text] [Related]
18. [Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital].
Li X; Tang J; Meng F; Li C; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2783-5. PubMed ID: 22292364
[TBL] [Abstract][Full Text] [Related]
19. [Analysis on 315 cases of clinical adverse drug reaction/event induced by gastrodin].
Zheng YY; Dong Z; Lu XQ; Xia YP; Zhu SB
Zhongguo Zhong Yao Za Zhi; 2015 May; 40(10):2037-41. PubMed ID: 26390669
[TBL] [Abstract][Full Text] [Related]
20. [A postmarketing surveillance study on 31,724 patients using Dengzhan Xixin injection in hospital].
Li YY; Lei L; Xie YM
Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4757-61. PubMed ID: 27245018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
